Banner

Filgrastim Biosimilars Global Market Report 2023 – By Application (Oncology, Chronic And Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Infectious Diseases, Other Applications), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Type Of Manufacturing (In-House Manufacturing, Contract Manufacturing Oraganization) – Market Size, Trends, And Market Forecast 2023-2032

Starting Price : $5000.00 | Pages : 250 | Published : January 2023 | SKU CODE : h1159 | Delivery Time: 2-3 business days | Format :


Filgrastim biosimilars refer to a biosimilar that is intended to treat patients who suffer bone marrow damage from extremely high radiation doses in a manner similar to how it helps cancer patients by stimulating the formation of white blood cells, making patients less susceptible to infections.

The two main types of manufacturing for filgrastim biosimilars are in-house manufacturing and contract manufacturing organization. A contract manufacturing organization, also known as a contract development and manufacturing organization, is a corporation that provides entire services to other pharma firms on a contractual basis, from drug discovery to drug production. The different applications include oncology, chronic and autoimmune diseases, blood disorders, growth hormone deficiency, infectious diseases, and others, and are distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies.

The filgrastim biosimilars market research report is one of a series of new reports from The Business Research Company that provides filgrastim biosimilars market statistics, including filgrastim biosimilars industry global market size, regional shares, competitors with a filgrastim biosimilars market share, detailed filgrastim biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the filgrastim biosimilars industry. This filgrastim biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The global filgrastim biosimilars market grew from $0.88 billion in 2022 to $0.95 billion in 2023 at a compound annual growth rate (CAGR) of 8.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The filgrastim biosimilars market is expected to grow from $1.33 billion in 2027 at a CAGR of 8.9%.

Government initiatives for the development of biosimilars are expected to drive the filgrastim biosimilars market over the coming years. Governments worldwide are focusing on the development of biosimilars due to their cost-effective nature. The US Food and Drug Administration (FDA) launched a Biosimilar Action Plan, to increase treatment options. The Australian government is committed to the Biosimilar Awareness Initiative, and they improved their commitment by supporting the Generic and Biosimilar Medicines Association through a grant of $5 million to accept increased general biosimilar education and activities that promote the suitable dispensing, prescription, and use of biosimilar medicines. Hence, the government's initiatives for the development of biosimilars aid in the increased production and awareness that, in turn, support the growth of the filgrastim biosimilars market.

Stringent regulations imposed on approvals of biosimilars are anticipated to hinder the growth of the filgrastim biosimilar market in the forecast period. The governments of different regions impose different rules regarding the production and use of biologics and biosimilars. Further, issues such as patent infringement or agreement issues restrict the manufacturers of biosimilars from commercialising the government-approved biosimilars. The US Food and Drug Administration requires double regulatory approval for biosimilars, restricting the use of biosimilars as interchangeable drugs for biologics, whereas, in Europe, the European Medicines Agency (EMA) approves biosimilars as interchangeable products for biologics. Sandoz, for example, received FDA approval for its first biosimilar, ZarxioTM (filgrastim-and) of the original biologic Neupogen.The consent depended on a comprehensive package of analytical, nonclinical, and clinical information, that verified that Zarxio is highly similar to the US-licensed reference product. To get this approval, Sandoz even had to fight a legal battle with Amgen, which claims that Sandoz has infringed on its manufacturing process. These kinds of hurdles can restrict the growth of the filgrastim biosimilar market.

Companies in the pegfilgrastim biosimilar market are increasing their product innovation through strategic collaborations. To sustain themselves in the increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated with academic and research institutions in this market by way of partnerships or out-licensing deals, this trend has been increasing over the past few years. For instance, in April 2020, Biocon, an India-based biopharmaceutical company, partnered with Mylan, a US-based generic and specialty pharmaceuticals company, to introduce Fulphila, a biosimilar pegfilgrastim, in Australia. Fulphila has been licenced by the Therapeutic Goods Administration for the therapy of oncology patients who have had chemotherapy to shorten the length of acute neutropenia and hence the risk of infection, as evidenced by febrile neutropenia.

In March 2022, Biocon Biologics, an India-based fully integrated biopharmaceutical company, acquired Viatris Inc. for $3.3 billion. This acquisition would build a distinctive, fully integrated, global biosimilars enterprise. This strategic alliance combines the strengths and complementary skills of both parties, positioning Biocon Biologics for the next ten years of value generation for all of our stakeholders. Viatris Inc. is a US-based pharmaceutical company that has developed a biosimilar of pegfilgrastim.

Major players in the filgrastim biosimilars market are Cadila Pharmaceuticals, Dr. Reddy's Laboratories, Intas Biopharmaceuticals, Sandoz, Amgen Inc., Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals, Emcure Pharmaceuticals Ltd., Biocon, and Aryogen Biopharma.

North America was the largest region in the filgrastim biosimilars market in 2022. The Middle East is expected to be the fastest growing region in the global filgrastim biosimilars market during the forecast period. The regions covered in the global filgrastim biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

The countries covered in the filgrastim biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA.

The filgrastim biosimilars consist of sales of Zarxio, Nivestym, and Releuko. Values in this market are "factory gate values," that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products.

The global filgrastim biosimilars market is segmented -

1) By Application: Oncology, Chronic And Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Infectious Diseases, Other Applications

2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

3) By Type Of Manufacturing: In-House Manufacturing, Contract Manufacturing Organizations

    Table Of Contents

    1. Executive Summary

    2. Filgrastim Biosimilars Market Characteristics

    3. Filgrastim Biosimilars Market Trends And Strategies

    4. Filgrastim Biosimilars Market – Macro Economic Scenario

    4.1 COVID-19 Impact On Filgrastim Biosimilars Market

    4.2 Ukraine-Russia War Impact On Filgrastim Biosimilars Market

    4.3 Impact Of High Inflation On Filgrastim Biosimilars Market

    5. Filgrastim Biosimilars Market Size And Growth

    5.1. Global Filgrastim Biosimilars Historic Market, 2017-2022, $ Billion

    5.1.1. Drivers Of The Market

    5.1.2. Restraints On The Market

    5.2. Global Filgrastim Biosimilars Forecast Market, 2022-2027F, 2032F, $ Billion

    5.2.1. Drivers Of The Market

    5.2.2. Restraints On the Market

    6. Filgrastim Biosimilars Market Segmentation

    6.1. Global Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Oncology

    Chronic and Autoimmune Diseases

    Blood Disorders

    Growth Hormone Deficiency

    Infectious Diseases

    Other Applications

    6.2. Global Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Hospital Pharmacy

    Retail Pharmacy

    Online Pharmacy

    6.3. Global Filgrastim Biosimilars Market, Segmentation By Type of Manufacturing, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    In-House Manufacturing

    Contract Manufacturing Oraganization

    7. Filgrastim Biosimilars Market Regional And Country Analysis

    7.1. Global Filgrastim Biosimilars Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    7.2. Global Filgrastim Biosimilars Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    8. Asia-Pacific Filgrastim Biosimilars Market

    8.1. Asia-Pacific Filgrastim Biosimilars Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    8.3. Asia-Pacific Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    9. China Filgrastim Biosimilars Market

    9.1. China Filgrastim Biosimilars Market Overview

    9.2. China Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

    9.3. China Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

    10. India Filgrastim Biosimilars Market

    10.1. India Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    10.2. India Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    11. Japan Filgrastim Biosimilars Market

    11.1. Japan Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    11.2. Japan Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    12. Australia Filgrastim Biosimilars Market

    12.1. Australia Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    12.2. Australia Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    13. Indonesia Filgrastim Biosimilars Market

    13.1. Indonesia Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    13.2. Indonesia Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    14. South Korea Filgrastim Biosimilars Market

    14.1. South Korea Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    14.2. South Korea Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    15. Western Europe Filgrastim Biosimilars Market

    15.1. Western Europe Filgrastim Biosimilars Market Overview

    15.2. Western Europe Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    15.3. Western Europe Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    16. UK Filgrastim Biosimilars Market

    16.1. UK Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    16.2. UK Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    17. Germany Filgrastim Biosimilars Market

    17.1. Germany Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    17.2. Germany Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    18. France Filgrastim Biosimilars Market

    18.4. France Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    18.5. France Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    19. Eastern Europe Filgrastim Biosimilars Market

    19.1. Eastern Europe Filgrastim Biosimilars Market Overview

    19.2. Eastern Europe Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    19.3. Eastern Europe Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    20. Russia Filgrastim Biosimilars Market

    20.1. Russia Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    20.2. Russia Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    21. North America Filgrastim Biosimilars Market

    21.1. North America Filgrastim Biosimilars Market Overview

    21.2. North America Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    21.3. North America Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    22. USA Filgrastim Biosimilars Market

    22.1. USA Filgrastim Biosimilars Market Overview

    22.2. USA Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    22.3. USA Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    23. South America Filgrastim Biosimilars Market

    23.1. South America Filgrastim Biosimilars Market Overview

    23.2. South America Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    23.3. South America Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    24. Brazil Filgrastim Biosimilars Market

    24.1. Brazil Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    24.2. Brazil Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    25. Middle East Filgrastim Biosimilars Market

    25.1. Middle East Filgrastim Biosimilars Market Overview

    25.2. Middle East Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    25.3. Middle East Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    26. Africa Filgrastim Biosimilars Market

    26.1. Africa Filgrastim Biosimilars Market Overview

    26.2. Africa Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    26.3. Africa Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    27. Filgrastim Biosimilars Market Competitive Landscape And Company Profiles

    27.1. Filgrastim Biosimilars Market Competitive Landscape

    27.2. Filgrastim Biosimilars Market Company Profiles

    27.2.1. Cadila Pharmaceuticals

    27.2.1.1. Overview

    27.2.1.2. Products and Services

    27.2.1.3. Strategy

    27.2.1.4. Financial Performance

    27.2.2. Dr. Reddy's Laboratories

    27.2.2.1. Overview

    27.2.2.2. Products and Services

    27.2.2.3. Strategy

    27.2.2.4. Financial Performance

    27.2.3. Intas Biopharmaceuticals

    27.2.3.1. Overview

    27.2.3.2. Products and Services

    27.2.3.3. Strategy

    27.2.3.4. Financial Performance

    27.2.4. Sandoz

    27.2.4.1. Overview

    27.2.4.2. Products and Services

    27.2.4.3. Strategy

    27.2.4.4. Financial Performance

    27.2.5. Amgen Inc.

    27.2.5.1. Overview

    27.2.5.2. Products and Services

    27.2.5.3. Strategy

    27.2.5.4. Financial Performance

    28. Filgrastim Biosimilars Pipeline Analysis

    29. Key Mergers And Acquisitions In The Filgrastim Biosimilars Market

    30. Filgrastim Biosimilars Market Future Outlook and Potential Analysis

    31. Appendix

    31.1. Abbreviations

    31.2. Currencies

    31.3. Historic And Forecast Inflation Rates

    31.4. Research Inquiries

    31.5. The Business Research Company

    31.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2017-2022, $ Billion
  • Table 2: Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
  • Table 3: Global Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 4: Global Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 5: Global Filgrastim Biosimilars Market, Segmentation By Type of Manufacturing, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 6: Global Filgrastim Biosimilars Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 7: Global Filgrastim Biosimilars Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 8: Asia-Pacific, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 9: Asia-Pacific, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 10: China, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 11: China, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 12: India, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 13: India, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 14: Japan, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 15: Japan, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 16: Australia, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 17: Australia, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 18: Indonesia, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 19: Indonesia, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 20: South Korea, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 21: South Korea, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 22: Western Europe, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 23: Western Europe, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 24: UK, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 25: UK, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 26: Germany, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 27: Germany, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 28: France, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 29: France, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 30: Eastern Europe, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 31: Eastern Europe, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 32: Russia, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 33: Russia, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 34: North America, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 35: North America, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 36: USA, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 37: USA, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 38: South America, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 39: South America, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 40: Brazil, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 41: Brazil, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 42: Middle East, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 43: Middle East, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 44: Africa, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 45: Africa, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 46: Cadila Pharmaceuticals Financial Performance
  • Table 47: Dr. Reddy's Laboratories Financial Performance
  • Table 48: Intas Biopharmaceuticals Financial Performance
  • Table 49: Sandoz Financial Performance
  • Table 50: Amgen Inc. Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2017-2022, $ Billion
  • Figure 2: Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
  • Figure 3: Global Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 4: Global Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 5: Global Filgrastim Biosimilars Market, Segmentation By Type of Manufacturing, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 6: Global Filgrastim Biosimilars Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 7: Global Filgrastim Biosimilars Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 8: Asia-Pacific, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 9: Asia-Pacific, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 10: China, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 11: China, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 12: India, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 13: India, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 14: Japan, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 15: Japan, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 16: Australia, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 17: Australia, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 18: Indonesia, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 19: Indonesia, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 20: South Korea, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 21: South Korea, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 22: Western Europe, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 23: Western Europe, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 24: UK, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 25: UK, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 26: Germany, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 27: Germany, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 28: France, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 29: France, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 30: Eastern Europe, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 31: Eastern Europe, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 32: Russia, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 33: Russia, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 34: North America, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 35: North America, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 36: USA, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 37: USA, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 38: South America, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 39: South America, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 40: Brazil, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 41: Brazil, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 42: Middle East, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 43: Middle East, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 44: Africa, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 45: Africa, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 46: Cadila Pharmaceuticals Financial Performance
  • Figure 47: Dr. Reddy's Laboratories Financial Performance
  • Figure 48: Intas Biopharmaceuticals Financial Performance
  • Figure 49: Sandoz Financial Performance
  • Figure 50: Amgen Inc. Financial Performance
View Report
View Report
View Report
View Report
View Report
View Report
View Report
View Report